Rhydum Sharma – författare

Medicinal and Aromatic Plants in the Post-Genomics Era brings together current research on species long valued for their therapeutic and industrial properties, now drawing renewed interest from the pharmaceutical, nutraceutical, cosmetic, and agricultural sectors amid rising demand for natural alternatives to synthetic chemistry.At the core of this shift is a deeper molecular understanding of how these plants produce their bioactive constituents. Genomics, transcriptomics, proteomics, and metabolomics have exposed the genetic architecture and biochemical pathways behind secondary metabolite synthesis, while computational biology helps make sense of the resulting complexity. Together, these tools are speeding up compound discovery and clarifying how such molecules function biologically.The chapters that follow turn this knowledge into practice: systems biology and metabolic engineering for boosting yields, CRISPR-based genome editing for reprogramming pathways, synthetic biology and AI-driven modeling for predicting and designing new biosynthetic routes, and emerging production platforms - from hairy root cultures to inducible expression systems - for expanding output sustainably.Taken together, the volume traces a progressive arc: from reading a plant's genetic blueprint to realizing its potential as a source of usable, real-world solutions in the clinic, the field, and the marketplace, offering a practical reference for both researchers and industry practitioners working at the intersection of plant biology and biotechnology.Introduces genome language models as a computational strategy for exploring plant genetic diversity relevant to secondary metabolite discovery.Includes detailed methodologies that support systematic analysis and interpretation of multi-omics datasets.Highlights the role of plant-associated microbes in enhancing host biosynthetic capacity, establishing an alternative route to conventional extraction techniques.Presents a therapeutic case study on indole-based heterocyclic compounds targeting MAP kinase signaling, illustrating how post-genomic discovery translates into specific anti-cancer drug candidates.